Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 236 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Buprenorphine-naloxone Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Providing Suboxone and PrEP Using Telemedicine

NCT04521920
View directory record Official record
Conditions
Opioid Use, Opioid-use Disorder, Risk Reduction, Hiv
Interventions
Suboxone, PrEP
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Charlotte, North Carolina • Durham, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Phase 2Phase 3 Interventional

Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine

NCT04991974
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Patient Navigation, Buprenorphine
Behavioral · Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

NCT02696434
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone, Placebo, Buprenorphine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 26, 2026, 1:45 AM EDT
Terminated Phase 1 Interventional

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

NCT06406400
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Not applicable Interventional

Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients

NCT02093559
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Overdose
Interventions
Brief counseling Intervention
Behavioral
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2

NCT00000299
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 26, 2026, 1:45 AM EDT
Completed No phase listed Observational Results available

Evaluation of Long-term Buprenorphine Plasma Exposure

NCT03752528
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Blood sample collection, Urine sample collection
Diagnostic Test
Lead sponsor
Indivior Inc.
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
11
States / cities
Hamilton, Alabama • Tampa, Florida • Prairie Village, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 26, 2026, 1:45 AM EDT
Withdrawn Phase 2 Interventional

Olanzapine in OUD Patients

NCT05179772
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Olanzapine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

NCT04976855
View directory record Official record
Conditions
Healthy Volunteer, Opioid-use Disorder
Interventions
INDV-2000, Placebo, SUBOXONE® sublingual film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Abuse Liability of Suboxone Versus Subutex

NCT00710385
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Heroin, Naloxone, Low Bup Dose, High Bup Dose, Low Bup/Nal Dose, High Bup/Nal Dose, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 26, 2026, 1:45 AM EDT
Terminated Phase 4 Interventional Results available

Buprenorphine as a Treatment in Opiate Dependent Pain Patients

NCT00552578
View directory record Official record
Conditions
Opiate Addiction, Refractory Pain
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2011 · Synced Sep 26, 2026, 1:45 AM EDT
Active, not recruiting Phase 2 Interventional

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

NCT04464980
View directory record Official record
Conditions
Opioid Use Disorder (OUD)
Interventions
SL-BUP, XR-BUP, XR-NTX, MM, MMR, MMD
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Little Rock, Arkansas • Tarzana, California • Bridgeport, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Phase 3 Interventional

Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1

NCT00015171
View directory record Official record
Conditions
Heroin Dependence, Substance-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 26, 2026, 1:45 AM EDT
Withdrawn Phase 4 Interventional

Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder

NCT04234516
View directory record Official record
Conditions
Opioid-use Disorder, Suicidal Ideation
Interventions
Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film, Morphine Sulfate 30 mg
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 26, 2026, 1:45 AM EDT
Withdrawn Phase 4 Interventional

Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents

NCT01015066
View directory record Official record
Conditions
Opiate Addiction
Interventions
Buprenorphine/naloxone, Naltrexone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
16 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Phase 1Phase 2 Interventional

CBT4CBT for Office Based Buprenorphine

NCT03580902
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
CBT4CBT-Buprenorphine, Buprenorphine/naloxone
Behavioral · Drug
Lead sponsor
CBT4CBT, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Group Medical Visits in Primary Care

NCT02526212
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
G-BMT, Treatment as usual, Buprenorphine
Behavioral · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 26, 2026, 1:45 AM EDT
Terminated Phase 4 Interventional Results available

Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients

NCT01841931
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence, Chronic Pain
Interventions
Buprenorphine/Naloxone
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 26, 2026, 1:45 AM EDT
Completed No phase listed Observational

Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions

NCT04049799
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome
Interventions
Medically-supervised withdrawal, Opioid agonist treatment, Comprehensive clinical care
Other · Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 26, 2026, 1:45 AM EDT
Not listed Phase 2 Interventional

Science-Based Treatment for Opioid-Dependent Adolescents

NCT00182572
View directory record Official record
Conditions
Opioid-Dependence Among Adolescents
Interventions
buprenorphine, naltrexone, behavior therapy, voucher-based contingency management
Drug · Procedure
Lead sponsor
National Development and Research Institutes, Inc.
Other
Eligibility
13 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2008 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

NCT04447287
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
ASP8062, Placebo ASP8062, buprenorphine/naloxone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

NCT04818086
View directory record Official record
Conditions
Drug Interaction, Analgesics, Opioid Use Disorder
Interventions
Lemborexant, Placebo, Buprenorphine-naloxone
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 26, 2026, 1:45 AM EDT
Completed Not applicable Interventional

Incentivizing Buprenorphine-Naloxone Initiation in Emergency Departments

NCT03821103
View directory record Official record
Conditions
Opioid Use
Interventions
Training, Behavioral economic enhanced arm
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 26, 2026, 1:45 AM EDT